Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy.

Thomas Powles; Michael Staehler; Börje Ljungberg; Karim Bensalah; Steven E Canfield; Saeed Dabestani; Rachel Giles; Fabian Hofmann; Milan Hora; Markus a Kuczyk; Thomas Lam; Lorenzo Marconi; Axel S Merseburger; Alessandro Volpe; Axel Bex

doi:10.1016/j.eururo.2015.10.017

Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy.

Thomas Powles, Michael Staehler, Börje Ljungberg, Karim Bensalah, Steven E Canfield, Saeed Dabestani, Rachel Giles, Fabian Hofmann, Milan Hora, Markus a Kuczyk, Thomas Lam, Lorenzo Marconi, Axel S Merseburger, Alessandro Volpe, Axel Bex

Clinic of Urology

98 Citations (Scopus)

Abstract

The European Association of Urology renal cancer guidelines have been updated to recommend nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of VEGF targeted therapy.

Original language	English
Journal	European Urology
Pages (from-to)	9-11
Number of pages	3
ISSN	0302-2838
DOIs	https://doi.org/10.1016/j.eururo.2015.10.017
Publication status	Published - 24.10.2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.eururo.2015.10.017

Cite this

@article{00d90e5674a845b693ce5a5ee01ae111,

title = "Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy.",

abstract = "The European Association of Urology renal cancer guidelines have been updated to recommend nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of VEGF targeted therapy.",

author = "Thomas Powles and Michael Staehler and B{\"o}rje Ljungberg and Karim Bensalah and Canfield, \{Steven E\} and Saeed Dabestani and Rachel Giles and Fabian Hofmann and Milan Hora and Kuczyk, \{Markus a\} and Thomas Lam and Lorenzo Marconi and Merseburger, \{Axel S\} and Alessandro Volpe and Axel Bex",

year = "2015",

month = oct,

day = "24",

doi = "10.1016/j.eururo.2015.10.017",

language = "English",

pages = "9--11",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy.

AU - Powles, Thomas

AU - Staehler, Michael

AU - Ljungberg, Börje

AU - Bensalah, Karim

AU - Canfield, Steven E

AU - Dabestani, Saeed

AU - Giles, Rachel

AU - Hofmann, Fabian

AU - Hora, Milan

AU - Kuczyk, Markus a

AU - Lam, Thomas

AU - Marconi, Lorenzo

AU - Merseburger, Axel S

AU - Volpe, Alessandro

AU - Bex, Axel

PY - 2015/10/24

Y1 - 2015/10/24

N2 - The European Association of Urology renal cancer guidelines have been updated to recommend nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of VEGF targeted therapy.

AB - The European Association of Urology renal cancer guidelines have been updated to recommend nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of VEGF targeted therapy.

U2 - 10.1016/j.eururo.2015.10.017

DO - 10.1016/j.eururo.2015.10.017

M3 - Journal articles

C2 - 26508312

SN - 0302-2838

SP - 9

EP - 11

JO - European Urology

JF - European Urology

ER -

Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy.

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this